Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Inclusion Criteria: * Subfoveal CNV secondary to AMD. * Central retinal (including lesion) thickness ≥ 250 µm as measured by OCT. * ETDRS best-corrected visual acuity (BCVA) of 20/40 to 20/400 (73 to 20 letters) Exclusion Criteria: * No prior treatment with the following in the study eye: * Subfoveal thermal laser therapy; * Submacular surgery or other surgical intervention for the treatment of AMD; * Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1 (Visit 2); * PDT or ITV administration of triamcinolone acetonide or any other steroid within 12 weeks prior to Day 1 (Visit 2); * Pegaptanib sodium within 8 weeks of Day 1 (Visit 2); * Juxtascleral steroids or anecortave acetate within 180 Days (6 months) prior to Day 1 (visit 2); * Prior systemic or intravitreal treatment with VEGF Trap or bevacizumab; * Any investigational agent for the treatment of eye disease within 12 weeks of Day 1 (Visit 2) * History of any vitreous hemorrhage within 4 weeks prior to baseline injection visit. * Aphakia or pseudophakia with the absence of a posterior capsule (unless it occurred as a result of a yttrium aluminum garnet \[YAG\] capsulotomy). * Significant subfoveal atrophy or scarring. * Any condition or laboratory abnormality that, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the subject's appropriate participation in this study